secwatch.observer — SEC 8-K summary
======================================

Issuer:     Virpax Pharmaceuticals, Inc. (—)
CIK:        0001708331
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001213900-24-039098
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Virpax CMO Jeffrey Gudin resigns as officer, continues as director; receives $81,900 severance
--------------------------------------------------------------------------------

- Jeffrey Gudin resigned as Chief Medical Officer and EVP on May 2, 2024; no disagreement cited.
- Separation agreement provides $81,900 paid semi-monthly over six months plus COBRA reimbursement.
- Unvested options for 5,358 shares will continue to vest; total options for 20,616 shares.
- Gudin remains a Class III Director of the company.
- Agreement includes general release and non-disparagement clauses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708331/000121390024039098/0001213900-24-039098-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708331/000121390024039098/ea0205136-8k_virpax.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-039098

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer